Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless”.

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID-19, the debilitating ...

Walmart Pharmacies to offer weight-loss drug making obesity treatment more accessible for millions nationwide.

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...